Axelson M, Sjövall J
Department of Clinical Chemistry, Karolinska Hospital, Stockholm, Sweden.
J Steroid Biochem. 1990 Aug 28;36(6):631-40. doi: 10.1016/0022-4731(90)90182-r.
The plasma concentrations of 3 beta-hydroxy-5-cholestenoic acid, 3 beta,7 alpha-dihydroxy-5-cholestenoic acid and 7 alpha-hydroxy-3-oxo-4-cholestenoic acid have been compared with that of 7 alpha-hydroxy-4-cholesten-3-one in healthy subjects and in patients with an expected decrease or increase of the bile acid production. In controls and patients with liver disease, the level of 7 alpha-hydroxy-3-oxo-4-cholestenoic acid was positively correlated to that of 3 beta,7 alpha-dihydroxy-5-cholestenoic acid and not to that of 7 alpha-hydroxy-4-cholesten-3-one. In patients with stimulated bile acid formation the levels of the acids were not correlated to each other but there was a significant positive correlation between the levels of 7 alpha-hydroxy-3-oxo-4-cholestenoic acid and 7 alpha-hydroxy-4-cholesten-3-one. These findings indicate that the precursor of 7 alpha-hydroxy-3-oxo-4-cholestenoic acid differs depending on the activity of cholesterol 7 alpha-hydroxylase. Since the activity of this enzyme is reflected by the level of 7 alpha-hydroxy-4-cholesten-3-one in plasma the findings are compatible with a formation of 7 alpha-hydroxy-3-oxo-4-cholestenoic acid from 3 beta,7 alpha-dihydroxy-5-cholestenoic acid when the rate of bile acid formation is normal or reduced and from 7 alpha-hydroxy-4-cholesten-3-one under conditions of increased bile acid synthesis. In support of this interpretation, 7 alpha,26-dihydroxy-4-cholesten-3-one was identified at elevated levels in plasma from patients with ileal resection or treated with cholestyramine. The levels of 7 alpha,12 alpha-dihydroxy-4-cholesten-3-one were also higher than normal in these patients. Based on these findings and previous knowledge, a model is proposed for the biosynthesis of bile acids in man. Under normal conditions, two major pathways, one "neutral" and one "acidic" or "26-oxygenated", lead to the formation of cholic acid and chenodeoxycholic acid, respectively. These pathways are separately regulated. When the activity of cholesterol 7 alpha-hydroxylase is high, the "neutral" pathway is most important whereas the reverse is true when cholesterol 7 alpha-hydroxylase activity is low. In cases with enhanced activity of cholesterol 7 alpha-hydroxylase, the "neutral" pathway is connected to the "acidic" pathway via 7 alpha,26-dihydroxy-4-cholesten-3-one, whereas a flow from the acidic pathway to cholic acid appears to be of minor importance.
在健康受试者以及胆汁酸生成预期减少或增加的患者中,对3β-羟基-5-胆甾烯酸、3β,7α-二羟基-5-胆甾烯酸和7α-羟基-3-氧代-4-胆甾烯酸的血浆浓度与7α-羟基-4-胆甾烯-3-酮的血浆浓度进行了比较。在对照组和肝病患者中,7α-羟基-3-氧代-4-胆甾烯酸的水平与3β,7α-二羟基-5-胆甾烯酸的水平呈正相关,而与7α-羟基-4-胆甾烯-3-酮的水平无关。在胆汁酸生成受刺激的患者中,这些酸的水平彼此不相关,但7α-羟基-3-氧代-4-胆甾烯酸和7α-羟基-4-胆甾烯-3-酮的水平之间存在显著正相关。这些发现表明,7α-羟基-3-氧代-4-胆甾烯酸的前体因胆固醇7α-羟化酶的活性而异。由于该酶的活性由血浆中7α-羟基-4-胆甾烯-3-酮的水平反映,因此这些发现与在胆汁酸生成速率正常或降低时由3β,7α-二羟基-5-胆甾烯酸形成7α-羟基-3-氧代-4-胆甾烯酸以及在胆汁酸合成增加的情况下由7α-羟基-4-胆甾烯-3-酮形成7α-羟基-3-氧代-4-胆甾烯酸的情况相符。为支持这一解释,在回肠切除患者或用消胆胺治疗的患者的血浆中,7α,26-二羟基-4-胆甾烯-3-酮的水平升高。这些患者中7α,12α-二羟基-4-胆甾烯-3-酮的水平也高于正常。基于这些发现和先前的知识,提出了一个人类胆汁酸生物合成的模型。在正常情况下,两条主要途径,一条“中性”途径和一条“酸性”或“26-氧化”途径,分别导致胆酸和鹅去氧胆酸的形成。这些途径是分别调节的。当胆固醇7α-羟化酶的活性高时,“中性”途径最重要,而当胆固醇7α-羟化酶活性低时则相反。在胆固醇7α-羟化酶活性增强的情况下,“中性”途径通过7α,26-二羟基-4-胆甾烯-3-酮与“酸性”途径相连,而从酸性途径到胆酸的流动似乎不太重要。